STOCK TITAN

Vanda Pharma Stock Price, News & Analysis

VNDA Nasdaq

Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.

Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical innovator developing therapies for complex medical conditions with limited treatment options. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.

Access real-time information about VNDA's sleep-wake disorder treatments, psychiatric therapies, and neurology pipeline. Our curated collection includes FDA decision updates, clinical trial results, financial earnings reports, and partnership announcements – all critical for understanding the company's market position.

Bookmark this page for streamlined tracking of Vanda's progress in antisense oligonucleotide research and commercialization efforts. Regular updates ensure you stay informed about HETLIOZ developments, Fanapt market performance, and emerging therapies in the company's clinical pipeline.

Rhea-AI Summary

Vanda Pharmaceuticals has received a revised unsolicited takeover proposal from Future Pak offering $7.25 to $7.75 per share in cash plus Contingent Value Rights. Vanda's Board of Directors will review the proposal to determine the best course of action. Shareholders do not need to take any action at this time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.22%
Tags
none
-
Rhea-AI Summary

Future Pak has increased its offer for Vanda Pharmaceuticals, including Contingent Value Rights (CVRs) along with $7.25 to $7.75 per share in cash. The increased offer could provide up to $260 million in potential value, translating to $11.62 to $12.12 per share, a 187% to 199% premium to Vanda's unaffected share price. Despite Vanda's actions to limit shareholder influence, Future Pak remains committed to the transaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.22%
Tags
none
-
Rhea-AI Summary

Vanda Pharmaceuticals will announce its first quarter 2024 financial results on May 8, 2024, followed by a conference call where management will discuss the results and corporate activities. Investors can participate by dialing in or accessing the webcast.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.38%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.38%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.38%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.16%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.56%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.81%
Tags

FAQ

What is the current stock price of Vanda Pharma (VNDA)?

The current stock price of Vanda Pharma (VNDA) is $4.36 as of August 15, 2025.

What is the market cap of Vanda Pharma (VNDA)?

The market cap of Vanda Pharma (VNDA) is approximately 257.6M.
Vanda Pharma

Nasdaq:VNDA

VNDA Rankings

VNDA Stock Data

257.63M
54.84M
7.16%
78.88%
7.78%
Biotechnology
Pharmaceutical Preparations
Link
United States
WASHINGTON